Jonas Ekblom

2.5k total citations · 1 hit paper
50 papers, 2.0k citations indexed

About

Jonas Ekblom is a scholar working on Molecular Biology, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Jonas Ekblom has authored 50 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 17 papers in Neurology and 14 papers in Cellular and Molecular Neuroscience. Recurrent topics in Jonas Ekblom's work include Parkinson's Disease Mechanisms and Treatments (11 papers), Amyotrophic Lateral Sclerosis Research (11 papers) and Neurotransmitter Receptor Influence on Behavior (9 papers). Jonas Ekblom is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (11 papers), Amyotrophic Lateral Sclerosis Research (11 papers) and Neurotransmitter Receptor Influence on Behavior (9 papers). Jonas Ekblom collaborates with scholars based in Sweden, United States and Italy. Jonas Ekblom's co-authors include Lars Oreland, Margit Mahlapuu, Håkan Garpenstrand, Camilla Björn, S. S. Jossan, Stefan Kammerer, Mikhail F. Denissenko, Peter Annas, Mats Fredrikson and Sten‐Magnus Aquilonius and has published in prestigious journals such as Neuroscience, Biochemical Pharmacology and Molecular Psychiatry.

In The Last Decade

Jonas Ekblom

50 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antimicrobial peptides as therapeutic agents: opportunities and challenges

2020 343 citations Jonas Ekblom et al. profile →

Peers

Countries citing papers authored by Jonas Ekblom

Since Specialization

Citations

This map shows the geographic impact of Jonas Ekblom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas Ekblom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas Ekblom more than expected).

Fields of papers citing papers by Jonas Ekblom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas Ekblom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas Ekblom. The network helps show where Jonas Ekblom may publish in the future.

Co-authorship network of co-authors of Jonas Ekblom

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas Ekblom. A scholar is included among the top collaborators of Jonas Ekblom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas Ekblom. Jonas Ekblom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals 2010 ·Rapid Communications in Mass Spectrometry ·Mehran Salehpour, Jonas Ekblom, (unknown), (unknown), Göran Possnert	8
2	Insulin: A new era for an old hormone☆ 2009 ·Pharmacological Research ·(unknown), Jonas Ekblom	16
3	Role of ICAM1 in invasion of human breast cancer cells 2005 ·Carcinogenesis ·Caridad Rosette, Richard B. Roth, Paul Oeth, Andreas Braun, Stefan Kammerer, Jonas Ekblom, Mikhail F. Denissenko	231
4	Production of a truncated soluble human semicarbazide-sensitive amine oxidase mediated by a GST-fusion protein secreted from HEK293 cells 2005 ·Protein Expression and Purification ·(unknown), Emma Jakobsson, (unknown), (unknown), (unknown), Christina Kalderén, (unknown), (unknown), Anna‐Lena Gustavsson, (unknown), Jonas Ekblom, Erik Holmgren, Magnus Doverskog, Lars Abrahmsén, Joakim Nilsson	4
5	IRESes: new potential drug targets? 2001 ·Drug Discovery Today ·Jonas Ekblom	2
6	Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2 2000 ·Life Sciences ·Mattias Damberg, Jonas Ekblom, Lars Oreland	29
7	Regulation of methionine adenosyltransferase catalytic activity and messenger RNA in SH-SY5Y human neuroblastoma cells 1998 ·Biochemical Pharmacology ·(unknown), Jonas Ekblom, Lars Oreland	8
8	Is there a “non-MAO” macromolecular target for L-rmdeprenyl?: Studies on MAOB mutant mice 1998 ·Life Sciences ·Jonas Ekblom, Lars Oreland, (unknown), (unknown)	12
9	Cytoprotection by Deprenyl and Tolcapone in a Cell Culture Model of Cerebral Ischaemia 1998 ·Pharmacology & Toxicology ·Jonas Ekblom, Olof Tottmar, Lars Oreland	2
10	A cell culture model of cerebral ischemia as a convenient system to screen for neuroprotective drugs 1998 ·Journal of neural transmission. Supplementum ·Jonas Ekblom, Håkan Garpenstrand, Olof Tottmar, Jonathan A. Prince, Lars Oreland	9
11	Levels ofl-MethionineS-Adenosyltranferase Activity in Erythrocytes and Concentrations ofS-Adenosylmethionine andS-Adenosylhomocysteine in Whole Blood of Patients with Parkinson's Disease 1997 ·Experimental Neurology ·Hong‐Ming Cheng, Cecilia Gomes–Trolin, S.‐M. Aquilonius, Alexandra Steinberg, (unknown), Jonas Ekblom, Lars Oreland	50
12	Biological Markers, with Special Regard to Platelet Monoamine Oxidase (trbc-MAO), for Personality and Personality Disorders 1997 ·Advances in pharmacology ·Lars Oreland, Jonas Ekblom, Håkan Garpenstrand, Jarmila Hallman	10
13	Monoamine oxidase gene transcription in human cell lines: Treatment with psychoactive drugs and ethanol 1996 ·Journal of Neural Transmission ·Jonas Ekblom, Qin‐shi Zhu, K. Chen, Jean C. Shih	12
14	Growth factor receptors in amyotrophic lateral sclerosis 1994 ·Molecular Neurobiology ·Abdu Adem, Jonas Ekblom, Per‐Göran Gillberg	15
15	Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis 1994 ·PubMed ·S. S. Jossan, Jonas Ekblom, (unknown), K E Hagbarth, S.‐M. Aquilonius	29
16	Neurodegeneration in amyotrophic lateral sclerosis : neurotrophic factors and monoamine oxidase B 1993 ·Jonas Ekblom	2
17	Immunotargeting with Monoclonal Cytokeratin 8 Antibodies of Human Urothelial Cancer Transplanted to Nude Mice 1993 ·Acta Oncologica ·Henry Letocha, Sten Nilsson, (unknown), Jonas Ekblom, Henrik Arnberg, (unknown), Jan‐Erik Westlin	5
18	Monoamine oxidase‐B in astrocytes 1993 ·Glia ·Jonas Ekblom, S. S. Jossan, (unknown), Lars Oreland, Erik Walum, Sten‐Magnus Aquilonius	107
19	Differential Increases in Catecholamine Metabolizing Enzymes in Amyotrophic Lateral Sclerosis 1993 ·Experimental Neurology ·Jonas Ekblom, S.‐M. Aquilonius, S. S. Jossan	14
20	Monoamine oxidase-B in motor cortex: Changes in amyotrophic lateral sclerosis 1992 ·Neuroscience ·Jonas Ekblom, S. S. Jossan, Per‐Göran Gillberg, L. Oreland, Sten‐Magnus Aquilonius	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact